The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2023 | The post-CAR prognostic index (PC-PI) for predicting OS in large B-cell lymphoma
Gloria Iacoboni, MD, Vall d’Hebron Institute of Oncology, Barcelona, Spain, discusses the Post-CAR Prognostic Index (PC-PI), which is a new prognostic score to predict the overall surivival (OS) in patients with large B-cell lymphoma (LBCL) who progress after receiving CAR T-cell therapy. Retrospective data were collected from 12 centers in Spain, and included 216 patients. The study showed that the PC-PI is a clinically useful tool to predict OS and risk-adapted treatment planning in patients who progress after receiving CAR T-cell therapy, and Dr Iacoboni eagerly anticipates its use for stratifying patients in the clinical trial setting. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Honoraria: AstraZeneca, MSD, Gilead Sciences, Celgene/Bristol-Myers Squibb, Novartis, Janssen, Miltenyi, AbbVie
Consultancy: Gilead Sciences, Celgene/Bristol-Myers Squibb, Novartis, Autolus, Miltenyi
